Biopharma grabs 55 new approvals in 2021

2020 and 2021 have definitely been Covid years ! Despite that, the Biopharma industry has been able to grab new 55 approvals in 2021, from molecular entities, biologics or cell therapies.

Among the most talked about are BioNTech/Pfizer Corminaty Covid-19 vaccine or Biogen's controversial Alzheimer drug Aduhelm.

This performance shows impressive resilience from the industry. Now, getting the most of those launches through omnichannel go-to-market and launch excellence is the critical next step.

This is where BlueJet Consulting can help !

Continue reading